Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4% After Insider Selling

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) dropped 4% during trading on Tuesday after an insider sold shares in the company. The stock traded as low as $37.63 and last traded at $37.31. Approximately 655,165 shares were traded during trading, a decline of 64% from the average daily volume of 1,803,260 shares. The stock had previously closed at $38.88.

Specifically, insider Peter Heerma sold 4,980 shares of the company’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $40.00, for a total value of $199,200.00. Following the sale, the insider directly owned 113,013 shares of the company’s stock, valued at $4,520,520. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Sandra Calvin sold 7,402 shares of the firm’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total value of $296,080.00. Following the transaction, the chief accounting officer directly owned 38,233 shares of the company’s stock, valued at $1,529,320. This represents a 16.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In other news, insider Jula Inrig sold 15,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $42.00, for a total value of $630,000.00. Following the sale, the insider directly owned 88,787 shares of the company’s stock, valued at $3,729,054. This represents a 14.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. TD Cowen boosted their price objective on shares of Travere Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Zacks Research cut Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Cowen reiterated a “buy” rating on shares of Travere Therapeutics in a research note on Friday, October 31st. Piper Sandler increased their target price on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a report on Friday, November 28th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $38.71.

Key Stores Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Recent quarter showed an upside surprise — Travere reported $0.28 EPS vs. a -$0.31 consensus and revenue of $164.9M (up ~162% y/y), which supports the company’s growth story. MarketBeat TVTX page
• Positive Sentiment: Large institutional buying: several hedge funds and managers (Adage, Armistice, Wellington, Stephens, Frazier) materially increased or established positions in recent quarters, signaling investor conviction at the institutional level. MarketBeat TVTX page
• Positive Sentiment: Analyst support: multiple firms (HC Wainwright, Citigroup, Wells Fargo) have reiterated/upgraded ratings or lifted targets; consensus price target around $38.7 reflects continued analyst interest. MarketBeat TVTX page
• Neutral Sentiment: Technical/market context — stock is trading above its 50‑day ($34.36) and 200‑day ($24.61) moving averages and remains nearer its 12‑month high than low, which can support momentum but may already be priced in. MarketBeat TVTX page
• Negative Sentiment: Clustered insider selling disclosed (Dec. 24): multiple insiders sold significant blocks — Peter Heerma (4,980 shares), Sandra Calvin (7,402), Jula Inrig (15,000) and William Rote (60,000). Large, simultaneous sales by executives can pressure shares and spook investors. SEC/Form 4 filings: Heerma Heerma Form 4, Calvin Calvin Form 4, Inrig Inrig Form 4, Rote Rote Form 4
• Negative Sentiment: Profitability and outlook remain a concern — the company reported negative net margin and ROE in the last quarter and analysts still expect a negative EPS for the year (consensus ~ -1.4), which caps valuation upside until sustained profits arrive. MarketBeat TVTX page
• Negative Sentiment: Leverage is notable (debt/equity ~4.23), which increases financial risk if revenue growth slows or margin pressures persist. MarketBeat TVTX page

Travere Therapeutics Stock Down 3.1%

The company has a fifty day simple moving average of $34.56 and a 200-day simple moving average of $24.77. The firm has a market cap of $3.37 billion, a P/E ratio of -35.55 and a beta of 0.89. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.59. The company had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. Travere Therapeutics’s quarterly revenue was up 162.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.70) EPS. On average, equities analysts anticipate that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TVTX. Raymond James Financial Inc. bought a new position in Travere Therapeutics during the second quarter valued at approximately $33,000. First Horizon Corp bought a new position in Travere Therapeutics during the third quarter valued at $36,000. Headlands Technologies LLC bought a new stake in Travere Therapeutics in the second quarter worth about $73,000. Atria Investments Inc bought a new position in Travere Therapeutics in the 2nd quarter valued at $154,000. Finally, Gallagher Fiduciary Advisors LLC bought a new stake in Travere Therapeutics during the 2nd quarter valued at about $155,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.